Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Real-time Estimate Cboe BZX
Other stock markets
 08:52:07 29/04/2024 pm IST 		5-day change 1st Jan Change
14.55 USD +6.28% Intraday chart for Sage Therapeutics, Inc. +10.78% -34.10%
25/04 Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained MT
25/04 Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
PR
Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained
MT
Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M
MT
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
BU
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor in the Treatment of Mild Cognitive Impairment in Parkinson's disease
AQ
TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating
MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating
MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating
MT
Top Midday Decliners
MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24
MT
Sector Update: Health Care Stocks Advance Premarket Wednesday
MT
Sector Update: Health Care
MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday
MT
Transcript : Sage Therapeutics, Inc. - Special Call
Top Premarket Decliners
MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint
MT
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
BU
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.